• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[泌尿系统癌症口服抗癌药物治疗的进展]

[Progress in oral anti-cancer drug therapy for urological cancer].

作者信息

Tsukamoto S, Akaza H

机构信息

Dept. of Urology, Hitachi General Hospital, Ibaraki, Japan.

出版信息

Gan To Kagaku Ryoho. 1999 Feb;26(3):308-14.

PMID:10065093
Abstract

We describe the progress in oral anti-cancer drug therapy for urological cancer. Pure antiandrogen (e.g., flutamide) is widely used as a means of maximal androgen blockade (MAB) in the treatment of prostate cancer. However, all series reported in the past several years did not show positive effects on prolongation of the patient's survival. Evaluations by meta-analysis are in progress. As the mechanism of antiandrogen withdrawal syndrome has been recognized, it was widely accepted that antiandrogen should be discontinued when disease progression or PSA elevation becomes evident. Estramustine was recently clarified as an effective therapeutic agent in the treatment of hormone refractory prostate cancer in combination with oral etoposide. Oral etoposide therapy has been tried as a maintenance or a palliative chemotherapy for non-curative or high-risk germ cell tumor. UFT (a compound of tegafur and uracil) is said to be effective for bladder cancer. It has been also suggested that UFT was partly effective as a means of first-line endocrine chemotherapy for advanced prostate cancer and was a promising agent in the treatment of advanced renal cell carcinoma in combination with Interferon-alpha. Usually the age of the patient with urological malignancy, excluding testicular cancer, is high and complicated. For such patients, an aggressive intravenous chemotherapy can not always be used. Therefore, a less aggressive, less toxic chemotherapy with oral drug is often planned to maintain QOL.

摘要

我们描述了泌尿系统癌症口服抗癌药物治疗的进展。单纯抗雄激素药物(如氟他胺)被广泛用作前列腺癌治疗中最大雄激素阻断(MAB)的一种手段。然而,过去几年报道的所有系列研究均未显示对延长患者生存期有积极作用。荟萃分析评估正在进行中。随着抗雄激素撤药综合征机制得到认识,人们普遍认为当疾病进展或前列腺特异性抗原(PSA)升高明显时应停用抗雄激素药物。雌莫司汀最近被明确为与口服依托泊苷联合用于治疗激素难治性前列腺癌的有效治疗药物。口服依托泊苷疗法已被尝试用于非治愈性或高危生殖细胞肿瘤的维持或姑息化疗。优福定(替加氟与尿嘧啶的复方制剂)据说对膀胱癌有效。也有人提出,优福定作为晚期前列腺癌一线内分泌化疗手段有部分疗效,并且与α干扰素联合使用时是治疗晚期肾细胞癌的一种有前景的药物。通常,除睾丸癌外,泌尿系统恶性肿瘤患者年龄较大且情况复杂。对于这类患者,并非总能采用积极的静脉化疗。因此,常计划采用侵袭性较小、毒性较低的口服药物化疗来维持生活质量。

相似文献

1
[Progress in oral anti-cancer drug therapy for urological cancer].[泌尿系统癌症口服抗癌药物治疗的进展]
Gan To Kagaku Ryoho. 1999 Feb;26(3):308-14.
2
[Effect of UFT on treatment of urological cancer--effect of UFT on treatment of invasive bladder cancer and advanced prostate cancer. Ibaraki Urological Cancer Chemotherapy Study Group].[优福定对泌尿生殖系统癌症的治疗效果——优福定对浸润性膀胱癌和晚期前列腺癌的治疗效果。茨城县泌尿生殖系统癌症化疗研究组]
Gan To Kagaku Ryoho. 1998 Jul;25(8):1179-87.
3
Clinical outcome of oral uracil/tegafur (UFT) therapy for patients with hormone refractory prostate cancer.口服尿嘧啶/替加氟(UFT)治疗激素难治性前列腺癌患者的临床结果。
Oncol Rep. 2005 Sep;14(3):673-6.
4
[The role of etoposide therapy in urogenital cancer].[依托泊苷疗法在泌尿生殖系统癌症中的作用]
Gan To Kagaku Ryoho. 1996 Dec;23(14):1929-35.
5
[Intermittent oral hormonal chemotherapy using estramustine phosphate and etoposide for the treatment of hormone-refractory prostate cancer].[使用磷酸雌莫司汀和依托泊苷的间歇性口服激素化疗治疗激素难治性前列腺癌]
Hinyokika Kiyo. 2003 Dec;49(12):709-14.
6
Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.初始最大雄激素阻断治疗后复发的晚期前列腺癌的替代性非甾体抗雄激素治疗
J Urol. 2008 Sep;180(3):921-7. doi: 10.1016/j.juro.2008.05.045. Epub 2008 Jul 17.
7
Endocrine treatment of prostate cancer.前列腺癌的内分泌治疗
J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95. doi: 10.1016/j.jsbmb.2004.10.005. Epub 2004 Dec 31.
8
Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial.每周使用紫杉醇、磷酸雌莫司汀和口服依托泊苷治疗激素难治性前列腺癌:米妮·珀尔癌症研究网络II期试验结果
Cancer. 2003 Nov 15;98(10):2192-8. doi: 10.1002/cncr.11790.
9
Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.氟他胺作为二线药物用于激素难治性前列腺癌最大雄激素阻断的效果。
Int J Urol. 2007 Mar;14(3):264-7. doi: 10.1111/j.1442-2042.2007.01681.x.
10
Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study.口服雌莫司汀与环磷酰胺治疗转移性激素难治性前列腺癌患者:一项II期研究。
Cancer. 2000 Mar 15;88(6):1438-44.